GET DAILY SIGNALSAbCellera Biologics (ABCL): Analyst Consensus Points to $18 Target and +50% Upside Potential
Key Takeaways
- The central $18 stock price target is the arithmetic mean of 11 verified analyst price targets, rounded to a clean level.
- AbCellera Biologics Inc. (ABCL) trades near $11.90, meaning the target requires a gain of roughly 50% from current levels.
- Individual analyst targets are unusually dispersed, ranging from a low of $9 to a high of $30, reflecting deep disagreement about the company's pipeline value.
- The strongest support comes from positive Phase 2 data for the menopause candidate ABCL635 and a large cash position of roughly $890 million.
- The biggest risks are continued losses, a rich valuation on a price-to-sales basis, and the inherent binary risk of clinical-stage biotech development.
- For additional context, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- Readers can also explore Trending AI Robots for automated, data-driven trading ideas.
Analyst Price Targets and the Consensus Outlook
AbCellera Biologics draws coverage from a range of Wall Street and Canadian research firms. Aggregating 11 current, individually attributed price targets yields a spread from about $9 to $30, with an arithmetic mean near $17.70 that rounds to the $18 central target referenced here. This aligns with several independent trackers showing an average near $17–$18 and a “Strong Buy” or “Buy” consensus rating, though it remains a calculated mean rather than an official published figure.
The spread stands out. Truist Financial’s Srikripa Devarakonda holds a $30 target, JonesTrading’s Debanjana Chatterjee sits at $25, and Jefferies’ Roger Song opened coverage at $21 in late October 2026. UBS placed an $18 target, J.P. Morgan $17, and BMO Capital $15. More measured views include Goldman Sachs and Stifel at $14, Piper Sandler at $12, and Bloom Burton at $9. Bullish analysts highlight the ABCL635 opportunity and the proprietary pipeline, while lower targets reflect ongoing questions around profitability and commercial execution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and the Path to the Target
With ABCL trading near $11.90, reaching $18 would require a gain of approximately 50%, a substantial move by most measures. The stock has already posted a strong recovery, rising from a 52-week low near $2.74 to a peak around $15 in late September 2026 before easing back.
The route to the target hinges on the company’s transition from a fee-for-service antibody-discovery model toward wholly owned clinical assets. The key driver has been ABCL635, a potential non-hormonal treatment for moderate-to-severe menopausal vasomotor symptoms, which delivered encouraging Phase 2 results. Additional 12-week and open-label data are expected in early 2027, with a pivotal Phase 3 program slated to start later that year.
Factors That Could Support a Move Toward the Target
Clinical validation remains the primary positive. The ABCL635 Phase 2 readout demonstrated a meaningful reduction in hot flashes, positioning the candidate as a potential blockbuster in an underserved market. A mid-2026 collaboration with Jazz Pharmaceuticals on a T-cell engager and progress on other candidates such as ABCL575 further broaden the pipeline. On the balance sheet, the company holds roughly $890 million in cash, which lowers near-term dilution risk, while a $200 million oversubscribed offering in 2026 signaled institutional interest. A series of new Buy initiations from Jefferies, UBS, and J.P. Morgan reflects improving sentiment and supports a higher average analyst price target.
Factors That Could Keep the Target Out of Reach
The main hurdle is that AbCellera remains unprofitable, with negative earnings per share and no clear path to profitability until products reach commercialization. On a price-to-sales basis the stock trades at a notable premium to the broader life-sciences sector, leaving little room for disappointment. Clinical-stage biotech also carries binary risk: any setback in the Phase 3 program for ABCL635, regulatory delay, or weaker follow-up data could compress the valuation quickly. Competition in the menopause space and potential sector rotation away from speculative growth names add further headwinds.
Technical Levels and Market Structure
The stock’s 52-week range runs from roughly $2.74 to $15.02. The area near $15, which aligns with the recent September high and a round psychological level, forms a key resistance zone. A move to $18 would require a decisive breakout above that prior peak and into territory last seen in the early post-IPO period. On the downside, the $9–$10 zone, where several analyst targets and recent consolidation levels cluster, provides a reference support area. The wide trading range highlights elevated volatility and limited technical conviction in either direction.
Time Horizon and Key Items to Watch
Most analyst price targets reflect a roughly 12-month research horizon, though individual firms may vary. Investors should monitor the early-2027 12-week and open-label ABCL635 data, the design and start of the pivotal Phase 3 program, quarterly cash burn and revenue trends, and any new partnership or licensing announcements. Additional analyst revisions, particularly upward target adjustments, and broader biotech sentiment will also influence the path toward $18.
Using AI Tools to Track Market Signals
In my own research process I frequently review Tickeron’s AI Daily Buy/Sell Signals to gain a systematic perspective on shifting conditions across thousands of stocks and ETFs. The platform applies artificial intelligence to monitor technical behavior and market dynamics, helping surface potential opportunities or changes in trend that complement traditional fundamental analysis. Traders looking for a data-driven layer alongside their own review can examine how the tool currently reads ABCL.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
ABCL sees its Stochastic Oscillator climbs out of oversold territory
On November 05, 2026, the Stochastic Oscillator for ABCL moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In 53 of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +12.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 207 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABCL as a result. In 78 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
ABCL moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ABCL crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ABCL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABCL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.296) is normal, around the industry mean (3.498). P/E Ratio (-22.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement